Literature DB >> 28721532

[Chronic cholestatic liver diseases : Differential diagnosis, pathogenesis and current treatment in adults].

S Hohenester1, U Beuers2.   

Abstract

In the long-term course chronic cholestasis regularly leads to fibrotic restructuring and ultimately to functional failure of the liver, independent of the cause. Cholestatic diseases are often clinically asymptomatic. In order to avoid progression, early diagnosis of the underlying disease and a targeted therapy are therefore decisive. The differential diagnoses of chronic cholestasis are broad; therefore, algorithms are of assistance in the diagnostic work-up. A better understanding of the pathogenesis is now leading to the development of new therapeutic agents in addition to ursodeoxycholic acid, which has long been known for its anticholestatic effects. Obeticholic acid and, in the near future, bezafibrate are therapeutic options. The possibilities for genetic diagnostics of unclear cholestasis syndromes improve the understanding of the pathogenesis of many diseases and are being introduced increasingly earlier into the clinical routine.

Entities:  

Keywords:  Cholangitis, biliary, primary; Cholangitis, sclerosing, primary; Cholestasis, intrahepatic; Obeticholic acid; Ursodeoxycholic acid

Mesh:

Substances:

Year:  2017        PMID: 28721532     DOI: 10.1007/s00108-017-0287-z

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  43 in total

Review 1.  Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review.

Authors:  Kirsten Boonstra; Ulrich Beuers; Cyriel Y Ponsioen
Journal:  J Hepatol       Date:  2012-01-13       Impact factor: 25.083

Review 2.  Potential of nor-Ursodeoxycholic Acid in Cholestatic and Metabolic Disorders.

Authors:  Michael Trauner; Emina Halilbasic; Thierry Claudel; Daniel Steinacher; Claudia Fuchs; Tarek Moustafa; Marion Pollheimer; Elisabeth Krones; Christian Kienbacher; Stefan Traussnigg; Lili Kazemi-Shirazi; Petra Munda; Harald Hofer; Peter Fickert; Gustav Paumgartner
Journal:  Dig Dis       Date:  2015-05-27       Impact factor: 2.404

Review 3.  Genetics in PSC: what do the "risk genes" teach us?

Authors:  Trine Folseraas; Evaggelia Liaskou; Carl A Anderson; Tom H Karlsen
Journal:  Clin Rev Allergy Immunol       Date:  2015-06       Impact factor: 8.667

4.  Optimizing biochemical markers as endpoints for clinical trials in primary biliary cirrhosis.

Authors:  Njideka Momah; Marina G Silveira; Roberta Jorgensen; Emmanouil Sinakos; Keith D Lindor
Journal:  Liver Int       Date:  2011-12-04       Impact factor: 5.828

5.  ACG Clinical Guideline: Primary Sclerosing Cholangitis.

Authors:  Keith D Lindor; Kris V Kowdley; M Edwyn Harrison
Journal:  Am J Gastroenterol       Date:  2015-04-14       Impact factor: 10.864

Review 6.  IgG4-related hepatobiliary disease: an overview.

Authors:  Emma L Culver; Roger W Chapman
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-09-14       Impact factor: 46.802

Review 7.  Mechanisms of tissue injury in autoimmune liver diseases.

Authors:  Evaggelia Liaskou; Gideon M Hirschfield; M Eric Gershwin
Journal:  Semin Immunopathol       Date:  2014-08-01       Impact factor: 9.623

8.  High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis.

Authors:  Keith D Lindor; Kris V Kowdley; Velimir A C Luketic; M Edwyn Harrison; Timothy McCashland; Alex S Befeler; Denise Harnois; Roberta Jorgensen; Jan Petz; Jill Keach; Jody Mooney; Carol Sargeant; Julie Braaten; Tamara Bernard; Debra King; Ellen Miceli; Jeff Schmoll; Tanya Hoskin; Prabin Thapa; Felicity Enders
Journal:  Hepatology       Date:  2009-09       Impact factor: 17.425

9.  A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis.

Authors:  Frederik Nevens; Pietro Andreone; Giuseppe Mazzella; Simone I Strasser; Christopher Bowlus; Pietro Invernizzi; Joost P H Drenth; Paul J Pockros; Jaroslaw Regula; Ulrich Beuers; Michael Trauner; David E Jones; Annarosa Floreani; Simon Hohenester; Velimir Luketic; Mitchell Shiffman; Karel J van Erpecum; Victor Vargas; Catherine Vincent; Gideon M Hirschfield; Hemant Shah; Bettina Hansen; Keith D Lindor; Hanns-Ulrich Marschall; Kris V Kowdley; Roya Hooshmand-Rad; Tonya Marmon; Shawn Sheeron; Richard Pencek; Leigh MacConell; Mark Pruzanski; David Shapiro
Journal:  N Engl J Med       Date:  2016-08-18       Impact factor: 91.245

10.  Immunoglobulin G4(+) B-cell receptor clones distinguish immunoglobulin G 4-related disease from primary sclerosing cholangitis and biliary/pancreatic malignancies.

Authors:  Marieke E Doorenspleet; Lowiek M Hubers; Emma L Culver; Lucas J Maillette de Buy Wenniger; Paul L Klarenbeek; Roger W Chapman; Frank Baas; Stan F van de Graaf; Joanne Verheij; Thomas M van Gulik; Eleanor Barnes; Ulrich Beuers; Niek de Vries
Journal:  Hepatology       Date:  2016-06-08       Impact factor: 17.425

View more
  1 in total

1.  Integrating Network Analysis and Metabolomics to Reveal Mechanism of Huaganjian Decoction in Treatment of Cholestatic Hepatic Injury.

Authors:  Qin Dong; Jiao Chen; Yan-Ping Jiang; Zong-Ping Zhu; Yong-Feng Zheng; Jin-Ming Zhang; Zhen Zhang; Wen-Qing Chen; Shi-Yi Sun; Lan Pang; Xin Yan; Wan Liao; Chao-Mei Fu
Journal:  Front Pharmacol       Date:  2022-01-19       Impact factor: 5.810

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.